University of Vermont Medical Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Vermont Medical Center sits in the top decile of US sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count).

27 total trials 11 currently recruiting 12 completed early-phase tilt top decile by trial count

University of Vermont Medical Center: 27 sponsored US clinical trials, 11 recruiting.

University of Vermont Medical Center sponsors 27 registered US clinical trials on ClinicalTrials.gov, 11 of them currently recruiting, and 12 completed. 1 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Post-Prostatectomy, with 1 trials.

Top-decile sponsor footprint

University of Vermont Medical Center ranks in the top decile of sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 39/100

12 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

27 total, page 1 of 1

RECRUITING NA

Nutritional Prehabilitation to Improve Cancer Outcomes (N-PICO)

NCT07072377
RECRUITING Phase 2

Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial

NCT06974370
RECRUITING Phase 2

MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer

NCT06998342
RECRUITING Phase 2

Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial

NCT06778408
RECRUITING NA

Optimizing Aerobic Fitness in Older Adults

NCT06951620
RECRUITING NA

Avocado and Postprandial Responses

NCT06818032
RECRUITING NA

Multi-disciplinary Care for Brain Metastases

NCT06280300
RECRUITING NA

Care Coordination Educational Intervention Study for Patients from Rural Areas with Early Stage Cancer

NCT05723250
RECRUITING Phase 2

Venous Thromboembolism Prevention in Outpatients With Glioma

NCT05683808
RECRUITING NA

Remote Smoking Cessation in Hospitalized Cardiac Patients

NCT05738408
RECRUITING Phase 2

Pyridostigmine for the Treatment of Constipation in Parkinson Disease

NCT05603715
NOT YET RECRUITING NA

Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer

NCT07406594
COMPLETED NA

NMES in HF Patients to Improve Functional Recovery Following Hospitalization

NCT05338437
COMPLETED NA

Early Case Management on Recovery From a Cardiac Event in Women

NCT04693988
TERMINATED NA

Orthosis of Acute Traumatic Rib Fractures Via RibFx Belt for Pain Alleviation and Improved Pulmonary Function

NCT03846024
TERMINATED Phase 4

The Effect of Perioperative Intravenous Lidocaine Infusion on Opioid Consumption After Lumbar Spine Surgery

NCT03624985
COMPLETED NA

Full-fat Yogurt and Glucose Tolerance

NCT03577119
COMPLETED

Obesity Alters Lung Mechanics in Robotic Surgery

NCT04329910
TERMINATED NA

Risk Stratification in Primary Care Combined With Stratified-specific Physical Therapy Care for Low Back Pain

NCT03065894
COMPLETED NA

Pilot Study of the Vermont Family Based Approach in Primary Care Pediatrics

NCT04412590
COMPLETED NA

The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery

NCT02562924
COMPLETED Phase 1

Interim Buprenorphine: Leveraging Medication + Technology to Bridge Delays in Treatment Access

NCT02360007
COMPLETED

Evaluation Of Transperineal Ultrasound For Image Guidance In The Treatment Of Prostate Cancer in Men Following Prostatectomy

NCT02110667
COMPLETED

A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Insulin Study

NCT01916733
COMPLETED Phase 2

Efficacy of Varenicline in Ambivalent Smokers

NCT00595868
COMPLETED Phase 2

Incentive-based Smoking Cessation for Methadone Patients

NCT00718835
COMPLETED Phase 2

Effective Treatment for Prescription Opioid Abuse

NCT00719095

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 8
Phase 4 1

Therapeutic Areas

Post-Prostatectomy 1
Palliative Radiotherapy 1
Nutritional Interventions 1
Nutritional Support 1
Quality of Life (QOL) 1
Cancer-related Malnutrition 1
Healthy Non-smokers 1
Healthy Volunteers Only 1
Healthy Male and Female Subjects 1
Malnutrition 1

What is open in the University of Vermont Medical Center pipeline

11 recruiting of 27 indexed (41% open); 12 completed (44%).

Phase mix: 1 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Post-Prostatectomy (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Vermont Medical Center: open-pipeline peers nationwide

Peers matched on 27 registered trials and 41% open enrollment, not the therapeutic-area sidebar.

University of Vermont Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015202530 0%10%20%30%40%50% Total trials Recruiting share University of Vermont Medical CenterAkron Children's HospitalArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)AVEO PharmaceuticalsDompé Farmaceutici S.p.AUniformed Services University of the Health SciencesKansas City Heart Rhythm Research FoundationAd scientiamAlto Neuroscience
University of Vermont Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Vermont Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 27 trials (± recruiting share)

Sponsors near 41% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Vermont Medical Center page

27 registered trials is a research-attention snapshot, not an endorsement of University of Vermont Medical Center or any single study.

  • 11 of University of Vermont Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Post-Prostatectomy is the condition University of Vermont Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Post-Prostatectomy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Vermont Medical Center pipeline card: 27 registered trials from official public datasets.Report a data error.